NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Deutsche from Hold to Buy. $28 price target. Emerging opportunity in virtualization is significant.
rated new Neutral at JP Morgan. $13 price target. Stock appears reasonably valued at current levels.
downgraded at Barclays to Underweight from Equal Weight as the company cuts back on investment spending. Price target lowered to $66 from $68. 2009 and 2010 EPS estimates dropped to $4.75 and $5.09, respectively.
rated new Buy at Goldman. Valuation call, based on a $111 price target.
upgraded at Citigroup from Hold to Buy. $92 price target. Internal execution is improving and organic growth should exceed expectations in 2010.
numbers increased at FBR. Shares now seen reaching $100. Estimates also raised, to match the company's new guidance for organic growth. Outperform rating.
rated new Buy at Goldman. Stock also placed on the Conviction Buy list. $80 price target. Company should post strong earnings growth over the next several years.
rated new Neutral at Goldman. Coverage of VMC was started with a Neutral rating. $55 price target.
rated new Overweight at Morgan Stanley. $32 price target. Market is underestimating the company's earnings power.
STOCK COMMENTS / EPS CHANGES
target lowered at Goldman to $14. Earnings have troughed and inventory is at a high level. Neutral rating.
estimate cut at Barclays. Barclays lowered AGCO 2010 EPS estimate to $1.35 from $1.50, 2009 maintained at $1.40. Reiterate Equal Weight rating and $32 price target.
estimates, target increased at Goldman. Estimates were raised through 2011. Buyback program should add to earnings. Neutral rating and new $162 price target.
estimates raised at Goldman through 2013. Company will likely see higher margins in the pharma distribution segment. Buy rating and $36 price target.
Dr. Pepper Snapple
target higher, estimates changed at Barclays. DPS price target raised by a dollar to $33. 2009 EPS estimate lowered to $1.96, 2010 lifted to $2.40. Maintain Overweight rating.
estimates boosted at Barclays. DV 2010 and 2011 EPS estimates increased to $3.17 and $3.70, respectively. Maintain Overweight rating and $68 price target.
estimates, target increased at UBS. Shares now seen reaching $99. Estimates also boosted, following the company's positive pre-announcement. Neutral rating.
price target higher at BofA/Merrill. Bank of America/Merrill Lynch raised GD price target to $80 from $74. Reiterate Buy rating.
estimates lowered at Morgan Stanley. HRB estimates were reduced through 2012. Company will likely not see much of a turnaround until 2011. Equal-weight rating.
estimates, target raised at UBS. HRB estimates were boosted through 2011. Resolution of legal dispute could allow the company to begin repurchasing stock. Buy rating and new $30 price target.
target, estimates cut at Barclays. KR price target by 2 dollars to $26. 2010 and 2011 EPS estimates dropped to $1.65 and $1.75, respectively. Maintain Overweight rating.
estimate higher at Barclays. MAR 2009 EPS estimate raised to $0.91 from $0.84, 2010 maintained at $0.85. Reiterate Underweight rating and $14 price target.
target, estimates raised at BofA/Merrill Lynch. Price target raised by 2 dollars to $46. 09/10/11 EPS estimates boosted to $3/$4.15/$4.85 from $2.80/$4.05/$4.80, respectively. Reiterate Buy rating.
estimate increased at Barclays. MMM 2010 EPS estimate to $5 from $4.95, 2009 maintained at $4.60. Reiterate Equal Weight rating and $90 price target.
estimate higher at Barclays. Barclays raised MTN 2010 EPS estimate to $0.89 from $0.87. Reiterate Overweight rating and $43 price target.
estimates higher at Credit Suisse. PBY 2010 and 2011 EPS estimate increased to $0.26 and $0.35, respectively. Maintain Neutral rating and $9 price target, Credit Suisse said.
estimates lowered at Goldman through 2011. Company is facing higher corporate expenses.
price target higher at Barclays. PNM price target raised by 50 cents to $12. 2009 and 2010 EPS estimates maintained at $0.79 and $0.64, respectively. Equal Weight rating.
price target boosted at Barclays to $58 from $54. 2009 EPS estimate maintained at $1.45, 2010 raised to $1.80. Reiterate Overweight rating.
numbers boosted at FBR. Shares of TXN now seen reaching $33. Estimates also raised, to match the company's new guidance for higher demand . Outperform rating.
estimates, target raised at Goldman. XLNX estimates were boosted through 2012. Company raised guidance, suggesting improved communications and industrial demand. Neutral rating and new $25 price target.
target, estimates boosted at Barclays. Barclays raised XLNX price target to $28 from $26. 2010 and 2011 EPS estimates increased to $1.20 and $1.58, respectively. Reiterate Overweight rating.
This article was written by a staff member of TheStreet.com.